<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02553382</url>
  </required_header>
  <id_info>
    <org_study_id>15-111</org_study_id>
    <nct_id>NCT02553382</nct_id>
  </id_info>
  <brief_title>Fibre Grain Herb Trial in Type 2 Diabetes</brief_title>
  <acronym>FIGHT</acronym>
  <official_title>Co-administration of Three Complimentary Therapies (Viscous Dietary Fiber, Whole Grain and Ginseng) for Comprehensive Risk Reduction in Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unity Health Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Unity Health Toronto</source>
  <brief_summary>
    <textblock>
      Despite the availability of multiple medications for the treatment of Type 2 diabetes,&#xD;
      patients often continue to have difficulty attaining blood glucose targets and managing&#xD;
      cardiovascular disease risk factors. Recent trends in non-pharmacological therapy have&#xD;
      created a growing public interest in dietary supplements.&#xD;
&#xD;
      Research by this group and others support the benefits of whole grains, viscous dietary fibre&#xD;
      and ginseng in the management of diabetes. The current study investigates whether the&#xD;
      co-administration of a viscous dietary fibre blend, Salba (a grain rich in omega-3 fatty&#xD;
      acids), and 2 varieties of ginseng roots will further improve blood sugar control and&#xD;
      cardiovascular disease risk outcomes in individuals with Type 2 diabetes already receiving&#xD;
      conventional treatments.&#xD;
&#xD;
      Patients with Type 2 diabetes receiving the recommended intervention in accordance with the&#xD;
      Canadian Diabetes Association guidelines will be enrolled in a 6-month clinical study. Half&#xD;
      of the participants will be randomly assigned to a 4-component intervention that comprises&#xD;
      the co-administration of these four dietary/herbal supplements in addition to their usual&#xD;
      treatment regimen; the other half will continue their usual treatment regimen in addition to&#xD;
      taking high-oat fiber and wheat bran supplements.&#xD;
&#xD;
      The investigators hypothesize that an intensified, multi-targeted intervention with the&#xD;
      addition of these dietary and herb components will further improve long-term blood glucose&#xD;
      control and cardiovascular disease risk factors beyond conventional therapy. If this&#xD;
      combination of viscous fiber, Salba and ginseng is shown to be beneficial, these remedies&#xD;
      could complement current conventional therapy for Type 2 diabetes with the goal to further&#xD;
      improve health outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via laboratory analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in LDL-C</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via laboratory analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24h ambulatory systolic blood pressure</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via analysis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in fasting glucose</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via laboratory analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in fasting insulin</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via laboratory analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in HOMA-IR</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via laboratory analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in total cholesterol</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via laboratory analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in triglycerides</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via laboratory analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in HDL-C</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via laboratory analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in total cholesterol:HDL-C</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via laboratory analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Non-HDL-C</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via laboratory analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Apo-B</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via laboratory analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in 24h diastolic BP</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in office systolic BP</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in office diastolic BP</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in central systolic BP</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in central diastolic BP</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Augmentation index at heart rate 75 bpm</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Hs-CRP</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Assessed via laboratory analysis</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Dietary, Herbal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary, Herbal</intervention_name>
    <description>Viscous fibre blend and Salba and American and Korean Red Ginseng capsules</description>
    <arm_group_label>Dietary, Herbal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Positive Control</intervention_name>
    <description>Oat bran blend and wheat bran capsules</description>
    <arm_group_label>Positive Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes medically diagnosed for at least 6-months prior to randomization&#xD;
&#xD;
          -  HbA1c (glycated hemoglobin) between 6.3% and 8.5% at screening&#xD;
&#xD;
          -  BMI &lt; 35 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Insulin therapy&#xD;
&#xD;
          -  Blood pressure â‰¥ 160/100 mmHg&#xD;
&#xD;
          -  Serum triglyceride &gt;4.5mmol/L&#xD;
&#xD;
          -  History of major cardiovascular events (stroke or myocardial infarction)&#xD;
&#xD;
          -  Gastrointestinal, liver or kidney disease&#xD;
&#xD;
          -  Consumption of alcohol &gt;2 drinks/day&#xD;
&#xD;
          -  Current tobacco smokers&#xD;
&#xD;
          -  Taking the following medications: herbs or supplements that may affect primary or&#xD;
             secondary outcomes, monoamine oxidase inhibitors (MAOIs) antidepressants and/or&#xD;
             anticoagulant therapy&#xD;
&#xD;
          -  Women with hormone sensitive tumors/conditions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>St. Michael's Hopsital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre Vuk Vrhovac, Merkur Hospital</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Croatia</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 30, 2015</study_first_submitted>
  <study_first_submitted_qc>September 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2015</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

